%0 Journal Article 
%A Retamozo, Soledad
%A Akasbi, Miriam
%A Brito Zeron, Pilar
%A Boshc, Xavier
%A Bove, Albert
%A Perez de Lis, Marta
%A Jimenez, Iratxe
%A Soto Cardenas, Maria Jose
%A Ramos-Casals, Manel
%A Soto Cardenas, María José
%A Gandia, Miriam
%A Diaz Lagares, Candido
%A Viñas, Odette
%A Siso, Antoni
%A Pérez Alvarez, Roberto
%A Yagüe, Jordi
%A Ramos-Casals, Manuel
%T Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome
%D 2012
%@ 1593-098X
%U http://hdl.handle.net/10498/39224
%X Abstract
OBJECTIVES:
To evaluate how determination of antibodies against the Ro52 antigen influences the classification and clinical characterisation of patients with suspected primary Sjögren`s syndrome (SS).
METHODS:
The cohort study included 187 patients who fulfilled at least four of the six 1993 SS classification criteria, including positive autoantibodies (antinuclear antibodies [ANA], rheumatoid factor [RF], anti-Ro/SSA and/or anti-La/SS-B antibodies) as mandatory criterium. Anti-Ro/SSA antibodies were tested by qualitative ELISA using a commercial assay. Anti-Ro52 antibodies were detected by a semiquantitative ELISA.
RESULTS:
Anti-Ro52 antibodies were found in 70/187 (37%) patients. A significant percentage of patients with anti-Ro/SSA antibodies were negative for anti-Ro52 antibodies (22%), while 13 patients (12%) were negative for anti-Ro/SSA antibodies but positive for anti-Ro52 antibodies, meaning that they fulfilled the 2002 SS criteria while avoiding the need for a salivary biopsy. Higher mean titers of anti-Ro52 antibodies were associated with severe scintigraphic involvement, positive salivary gland biopsy, parotid enlargement, anaemia, leukopenia and RF. A statistical correlation was found between anti-Ro52 titers and age, gammaglobulin levels, RF titers and serum IgA and IgG. Patients with positive anti-Ro/SSA and anti-Ro52 antibodies had a higher frequency of positive salivary gland biopsy, parotid enlargement and positive RF, and higher levels of serum IgG and IgA levels in comparison with patients with positive anti-Ro/SSA but negative anti-Ro52 antibodies.
CONCLUSIONS:
Anti-Ro52 antibodies were closely associated with the main clinical, histopathological and immunological features of primary SS. Anti-Ro52 autoantibody testing may help to identify a specific subset of SS patients with more aggressive disease, in whom a closer follow-up and earlier, more robust therapeutic management may be necessary.
%K Sjögren’s syndrome
%K Anri-Ro/SSA antibodies
%K anti-Ro52 antibodies
%~ Universidad de Cádiz